Emerging drugs for the treatment of herpetic keratitis
Expert Opinion on Emerging Drugs · 02.04.2024 · 29 (2) · 113-126
DOI: 10.1080/14728214.2024.2339899 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Opinion on Emerging Drugs, online erschienen am 11.04.2024. Verfasst von Divya Kapoor und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of Illinois at Chicago, Chicago, IL, USA. Hauptthemen laut MEDLINE: Keratitis, Herpetic, Antiviral Agents, Herpesvirus 1, Human, Drug Development. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS, NIAID NIH HHS, NIH RO1.
Abstract (Originalsprache)
INTRODUCTION: Herpes simplex keratitis stands as a prominent factor contributing to infectious blindness among developed nations. On a global scale, over 60% of the population tests positive for herpes simplex virus type-1 (HSV-1). Despite these statistics, there is currently no vaccine available for the virus. Moreover, the conventional nucleoside drugs prescribed to patients are proving ineffective in addressing issues related to drug resistance, recurrence, latency, and the escalating risk of vision loss. Hence, it is imperative to continually explore all potential avenues to restrict the virus. This review article centers on the present treatment methods for HSV-1 keratitis (HSK), highlighting the ongoing clinical trials. It delves into the emerging drugs, their mode-of-action and future therapeutics. AREAS COVERED: The review focuses on the significance of a variety of small molecules targeting HSV-1 lifecycle at multiple steps. Peer-reviewed articles and abstracts were searched in MEDLINE, PubMed, Embase, and clinical trial websites. EXPERT OPINION: The exploration of small molecules that target specific pathways within the herpes lifecycle holds the potential for substantial impact on the antiviral pharmaceutical market. Simultaneously, the pursuit of disease-specific biomarkers has the capacity to usher in a transformative era in diagnostics within the field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, University of Illinois at Chicago, Chicago, IL, USA.
- Department of Ophthalmology and Visual Sciences, University of Illinois Medical Center, Chicago, IL, USA.
Förderung
- NEI NIH HHS
- NIAID NIH HHS
- NIH RO1
- NEI core
Zitieren
APA
Kapoor, D., Sharma, P., & Shukla, D. (2024). Emerging drugs for the treatment of herpetic keratitis. Expert Opinion on Emerging Drugs, 29(2), 113-126. https://doi.org/10.1080/14728214.2024.2339899
Vancouver
Kapoor D, Sharma P, Shukla D. Emerging drugs for the treatment of herpetic keratitis. Expert Opinion on Emerging Drugs. 2024;29(2):113-126. doi:10.1080/14728214.2024.2339899
BibTeX
@article{Kapoor2024,
author = {Kapoor, Divya and Sharma, Pankaj and Shukla, Deepak},
title = {Emerging drugs for the treatment of herpetic keratitis},
journal = {Expert Opinion on Emerging Drugs},
year = {2024},
volume = {29},
number = {2},
pages = {113--126},
doi = {10.1080/14728214.2024.2339899}
}
EUVIMED